References
- Centers for Disease Control and PreventionNational diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011Atlanta, GAU.S. Department of Health and Human Services2011
- AtkinsonMAEisenbarthGSMichelsAWType 1 diabetesLancet201438369 8223890997
- BeckRWTamborlaneWVBergenstalRMMillerKMDuBoseSNHallCAThe T1D Exchange clinic registryJ Clin Endocrinol Metab2012974383 438922996145
- SeaquistERAndersonJChildsBHypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine SocietyDiabetes Care2013361384 139523589542
- CryerPEGlycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemiaDiabetes2014632188 219524962915
- SkrivarhaugTBangstadHJSteneLCSandvikLHanssenKFJonerGLong-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in NorwayDiabetologia200649298 30516365724
- PattersonCCDahlquistGHarjutsaloVEarly mortality in EURODIAB population-based cohorts of type 1 diabetes diagnosed in childhood since 1989Diabetologia2007502439 244217901942
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research GroupJacobsonAMMusenGLong-term effect of diabetes and its treatment on cognitive functionN Engl J Med20073561842 185217476010
- FeltbowerRGBodanskyHJPattersonCCAcute complication and drug misuse are important causes of death for children and young adults with type 1 diabetesDiabetes Care200831922 92618285550
- ZambrowiczBFreimanJBrownPMLX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trialClin Pharmacol Ther201292158 16922739142
- ZambrowiczBDingZMOgbaaIEffects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetesClin Ther201335273 28523433601
- RosenstockJCefaluWLapuertaPLX4211, a dual inhibitor of sodium glucose transporters SGLT1 and SGLT2, lowers A1c and improves cardiovascular risk factors in patients with type 2 diabetes: impact of LX4211 on diabetes CV risk factorsDiabetes Care Epub20149 11
- PowellDRSmithMGreerJLX4211 increases serum GLP-1 and PYY levels by reducing SGLT-1-mediated absorption of intestinal glucoseJ Pharmacol Exp Ther2013345250 25923487174
- PowellDRDaCostaCMSmithMEffects of LX4211 on glucose homeostasis and body composition in preclinical modelsJ Pharmacol Exp Ther2014350232 24224849925
- HaradaMMakinoSPromotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamideDiabetologia198427604 6066530055
- FaleoGFotinoCBoccaNPrevention of autoimmune diabetes and induction of β-cell proliferation in NOD mice by hyperbaric oxygen therapyDiabetes2012611769 177822566533
- PowellDRDaCostaCGayJImproved glycemic control in mice lacking Sglt1 and Sglt2Am J Physiol2013304E117 E130
- VallonVRoseMGerasimovaMKnockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitusAm J Physiol2013304F156 F167
- ChaparroRJDiLorenzoTPAn update on the use of NOD mice to study autoimmune (type 1) diabetesExpert Rev Clin Immunol20106939 95520979558
- GrantCWDuclosSKMoran-PaulCMDevelopment of standardized insulin treatment protocols for spontaneous rodent models of type 1 diabetesComp Med201262381 39023114041
- GuerciBTubiana-RufiNBauduceauBAdvantages to using capillary blood beta-hydroxybutyrate determination for the detection and treatment of diabetic ketosisDiabetes Metab200531401 40616369204
- BrescianiFPietraMCorradiniSGiuntiMFracassiFAccuracy of capillary blood 3-β-hydroxybutyrate determination for the detection and treatment of canine diabetic ketoacidosisJ Vet Sci201415309 31624675829
- FerranniniEMuscelliEFrascerraSMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsJ Clin Invest2014124499 50824463454
- MerovciASolis-HerreraCDanieleGDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose productionJ Clin Invest2014124509 51424463448